Long-term follow-up after flunarizine or nimodipine discontinuation in migraine patients

Cephalalgia

Volumn 16, Issue 5, 1996, Pages 337-340

  Nuti, A ^a   Lucetti, C ^a   Pavese, N ^a   Dell'Agnello, G ^a   Rossi, G ^b   Bonuccelli, U ^a  

^a UNIVERSITY OF PISA   (Italy)

^b INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

Flunarizine; Migraine nimodipine

Indexed keywords

FLUNARIZINE; NIMODIPINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HUMAN; MALE; MIGRAINE; NAUSEA; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; RECTAL DRUG ADMINISTRATION; SINGLE BLIND PROCEDURE; VERTIGO; VOMITING;

ADULT; CALCIUM CHANNEL BLOCKERS; FEMALE; FLUNARIZINE; FOLLOW-UP STUDIES; HUMANS; MALE; MIGRAINE DISORDERS; NIMODIPINE; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 0029741283     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.1996.1605337.x     Document Type: Article

References (29)

1. Fisher M, Grotta J. New uses for calcium channel blockers. Therapeutic implications. Drugs 1993;46(6):961-75
2. Leone M, Grazi L, La Mantia L, Bussone G. Flunarizine in migraine: a mini-review. Headache 1991;31:388-91
3. Olesen J. Calcium antagonists in migraine and vertigo. Possible mechanisms of action and review of clinical trials. Eur Neurol 1990;30: Suppl 2:31-4
4. Amery WK. Onset of action of various migraine prophylactics. Cephalalgia 1988;8: Suppl 8:11-3
5. Andersson KE, Vinge E. Beta-adrenoceptor blockers and calcium antagonists in the prophylaxis and treatment of migraine. Drugs 1990;39:355-73
6. Gelmers HJ. Nimodipine, a new calcium antagonist, in the prophylactic treatment of migraine. Headache 1983;23:106-9
7. Havanka-Kanniainen H, Hokkanen E, Myllyla VV. Efficacy of nimodipine in the prophylaxis of migraine. Cephalalgia 1985;5:39-43
8. Stewart DJ, Gelston A, Hakim A. Effect of prophylactic administration of nimodipine in patients with migraine. Headache 1988;28:260-2
9. Ansell E, Fazzone T, Festenstein R, Johnson ES, Thavapalan M. Nimodipine in migraine prophylaxis. Cephalalgia 1988;8: 269-72
10. Migraine-Nimodipine European Study Group (MINES). European multicenter trial of nimodipine in the prophylaxis of common migraine (migraine without aura). Headache 1989;29:633-8
11. Migraine-Nimodipine European Study Group (MINES). European multicenter trial of nimodipine in the prophylaxis of classic migraine (migraine with aura). Headache 1989; 29:639-42
12. Bussone G, Baldini S, D'Andrea G, Cananzi A, Frediani F, Caresia L, Ferro Milone F, Boiardi A. Nimodipine versus flunarizine in common migraine: a controlled pilot trial. Headache 1987;27:76-9
13. Bono G, Manzoni GC, Martucci N, Baldrati A, Farina S, Canbogi F, et al. Flunarizine in common migraine: Italian cooperative trial II. Long-term follow-up. Cephalalgia 1985;5 Suppl 2:155-8
14. Martinez-Lage JM. Flunarizine (Sibelium®) in the prophylaxis of migraine. An open, long-term, multicenter trial. Cephalalgia 1988;8 Suppl 8:15-20
15. Wober C, Wober-Bingol C, Koch G, Wessely P. Long-term results of migraine prophylaxis with flunarizine and beta-blockers. Cephalalgia 1991;11:251-6
16. Headache Classification of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8 Suppl 7:1-96
17. Toda N, Tfelt-Hansen P. Calcium antagonists. In: Olesen J, Tfelt-Hansen P, Welch KMA, editors. The headaches. New York: Raven Press, 1993:383-90
18. Tfelt-Hansen P, Welch KMA. General principles of pharmacological treatment. In: Olesen J, Tfelt-Hansen P, Welch KMA, editors. The headaches. New York: Raven Press, 1993:299-303
19. Peroutka SJ, Banghart SB, Allen GS. Relative potency and selectivity of calcium antagonists used in the treatment of migraine. Headache 1984;24:55-8
20. Wauquier A, Ashton D, Marranas R. The effects of flunarizine in experimental models related to the pathogenesis of migraine. Cephalalgia 1985;5: Suppl 2:119-23
21. 3H-ligand for serotonin receptor binding sites. Binding properties brain distribution and functional role. Mol Pharmacol 1982;21:301-14
22. Leysen JE, Gommeren W. In vitro receptor binding profile of drugs used in migraine. In: Amery WK, Van Nueten JM, Wauquier A, editors. The pharmacological basis of migraine therapy. London: Pitman, 1984:255-66
23. Wober C, Brucke T, Wober-Bingol C, Asenbaum S, Wessely P, Podreka I. Dopamine D2 receptor blockade and antimigraine action of flunarizine. Cephalalgia 1994; 14:235-40
24. Chouza C, Caamano JL, Aljanati R, Scaramelli A, De Medina O, Romero S. Parkinsonism, tardive dyskinesia, akathisia and depression induced by flunarizine. Lancet 1986;i:1303-4
25. Lugaresi A, Montagna P, Gallassi R, Lugaresi E. Extrapyramidal syndrome and depression induced by flunarizine. Eur Neurol 1988;28:208-11
26. Bonuccelli U, Piccini P, Paoletti AM, Nuti A, Colzi A, Melis GB, et al. Flunarizine increases PRL secretion in normal and migrainous women. J Neural Transm 1988;74:43-53
27. Piccini P, Nuti A, Paoletti AM, Napolitano A, Melis GB, Bonuccelli U. Possible involvement of dopaminergic mechanisms in the antimigraine action of flunarizine. Cephalalgia 1990;10:3-8
28. Formisano R, Falaschi P, Cerbo R, Proietti A, Catarci T, D'Urso R, et al. Nimodipine in migraine: clinical efficacy and endocrinological effects. Eur J Clin Pharmacol 1991;41:69-71
29. Soresen PS, Larsen BH, Rasmussen MJK, et al. Flunarizine versus metoprolol in migraine prophylaxis: a double-blind randomized parallel group study of efficacy and tolerability. Headache 1991;31:650-7